Fudan University
fudan.edu.cnTotal trials
1,226
Active
534
Phase 3
181
Total enrollment
1,242,472
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 522 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Capecitabine | — | 50 | |||||
| Huaier Granule | — | — | — | — | 8 | ||
| tunlametinib | — | — | — | — | 2 | ||
| Systematic chemotherapy | — | — | — | — | — | 1 | |
| Intrathecal chemotherapy | — | — | — | — | — | 1 | |
| Befotertinib | — | — | — | — | — | 1 | |
| Tongxinluo | — | — | — | — | — | 1 | |
| Anlotinib and Bevacizumab | — | — | — | — | — | 1 | |
| Inetetamab and Paclitaxel ± Pertuzumab | — | — | — | — | — | 1 | |
| dabrafenib plus trametinib with or without PD-1 antibody | — | — | — | — | — | 1 | |
| entrectinib or larotrectinib with or without anti-PD-1 antibdoy | — | — | — | — | — | 1 | |
| pralsetinib or selpercatinib with or without anti-PD-1 antibdoy | — | — | — | — | — | 1 | |
| anlotinib or anlotinib plus anti-PD-1 antibody | — | — | — | — | — | 1 | |
| lenvatinib plus anti-PD-1 antibody | — | — | — | — | — | 1 | |
| Other Targets: precise treatment based on the target | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | 33 | ||
| Camrelizumab | — | — | — | 19 | |||
| Chemotherapy | — | — | — | 19 | |||
| Paclitaxel | — | — | — | — | 18 | ||
| Gemcitabine | — | — | — | — | 21 | ||
| Carboplatin | — | — | — | — | 13 | ||
| SHR-A1811 | — | — | — | — | 9 | ||
| Trastuzumab | — | — | — | — | 13 | ||
| Nab paclitaxel | — | — | — | — | 12 | ||
| Docetaxel | — | — | — | — | 16 | ||
| Cyclophosphamide | — | — | — | — | 12 | ||
| Fluzoparib | — | — | — | — | 9 | ||
| Adebrelimab | — | — | 9 | ||||
| Epirubicin | — | — | — | 11 | |||
| Cisplatin | — | — | — | — | 14 | ||
| Famitinib | — | — | — | — | 7 | ||
| Apatinib | — | — | — | 15 | |||
| Nab-paclitaxel | — | — | — | — | 10 | ||
| PD-1 inhibitor | — | — | — | 5 | |||
| Pyrotinib | — | — | — | — | 9 | ||
| Everolimus | — | — | — | — | 6 | ||
| Pertuzumab | — | — | — | — | 4 | ||
| CDK4/6 Inhibitor | — | — | — | — | 3 | ||
| Endocrine therapy | — | — | — | — | — | 3 | |
| Abemaciclib | — | — | — | — | 3 |
482 more active programs hidden
Next readouts
- 2022-01-01
- 2022-05
- 2023-09-01
- 2023-12
- 2024-03-12
- 2024-03-30
- 2024-05-20
- 2024-06
- 2024-06
- 2024-06-30
Top conditions
- Breast Cancer141
- Colorectal Cancer58
- Hepatocellular Carcinoma33
- Gastric Cancer30
- Esophageal Squamous Cell Carcinoma28
- Pancreatic Cancer25
- Metastatic Breast Cancer25
- Nasopharyngeal Carcinoma21
Frequently asked questions about Fudan University
- How many clinical trials does Fudan University have on ClinicalTrials.gov?
- Fudan University is listed as the lead sponsor on 1,226 clinical trials in ClinicalTrials.gov, 534 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Fudan University's trials are in Phase 3?
- 181 of Fudan University's trials are in Phase 3, spread across 522 active drug programs.
- What therapeutic areas does Fudan University focus on?
- Fudan University's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Squamous Cell Carcinoma.
- When are Fudan University's next clinical trial readouts?
- Fudan University has 10 upcoming primary-completion readouts tracked here; the soonest is “S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）”, expected around 2022-01-01.